PapersFlow Research Brief
Natural Compounds in Disease Treatment
Research Guide
What is Natural Compounds in Disease Treatment?
Natural Compounds in Disease Treatment is the study of bioactive molecules derived from plants such as Celastrol and Triptolide from Thunder God Vine and Tripterygium wilfordii Hook F, applied to treat inflammatory disorders, cancer, and neurodegenerative diseases through mechanisms including NF-κB inhibition, apoptosis induction, and antioxidant activity.
Research on natural compounds in disease treatment encompasses 12,337 works focused on herbal medicines like Celastrol and Triptolide for conditions including rheumatoid arthritis and cancer. These compounds target pathways such as NF-κB signaling and proteasome inhibition, as shown in preclinical models. Studies demonstrate their roles in suppressing tumor growth and modulating apoptosis in multiple myeloma cells.
Topic Hierarchy
Research Sub-Topics
Celastrol in Cancer Therapy
Researchers investigate celastrol's mechanisms, including proteasome inhibition and apoptosis induction, in prostate, myeloma, and other cancers. Studies focus on its efficacy in preclinical models and clinical translation challenges.
Triptolide and Transcriptional Inhibition
This sub-topic explores triptolide's targeting of XPB and TFIIH in halting eukaryotic transcription for anti-cancer and anti-inflammatory effects. Research examines its specificity, toxicity, and combinatorial therapies.
NF-κB Inhibition by Natural Compounds
Studies celastrol and triptolide's suppression of NF-κB pathways in inflammation and cancer models. Researchers analyze signaling cascades, therapeutic windows, and synergies with conventional drugs.
Tripterygium wilfordii in Autoimmune Diseases
Focuses on Thunder God Vine extracts for rheumatoid arthritis and other autoimmune conditions via anti-inflammatory and immunosuppressive actions. Clinical trials assess safety, dosing, and long-term outcomes.
Natural Products in Neuroprotection
Examines celastrol and triptolide's antioxidant and anti-apoptotic roles in neurodegenerative diseases like Alzheimer's and Parkinson's. Research covers blood-brain barrier penetration and neuroprotective pathways.
Why It Matters
Natural compounds like Celastrol suppress human prostate cancer growth in nude mice by acting as a potent proteasome inhibitor, as demonstrated by Yang et al. (2006) in "Celastrol, a Triterpene Extracted from the Chinese “Thunder of God Vine,” Is a Potent Proteasome Inhibitor and Suppresses Human Prostate Cancer Growth in Nude Mice" with 576 citations. Celastrol treats obesity by targeting specific pathways, according to Liu et al. (2015) in "Treatment of Obesity with Celastrol" (701 citations). Thalidomide, revisited in this context, inhibits angiogenesis induced by basic fibroblast growth factor in rabbit cornea assays, per D’Amato et al. (1994) in "Thalidomide is an inhibitor of angiogenesis" (2455 citations), and induces apoptotic signaling in refractory multiple myeloma cells via immunomodulatory analogs, as reported by Mitsiades et al. (2002) (666 citations). Triptolide targets XPB, a subunit of TFIIH, offering potential for transcription-related therapies (Titov et al., 2011, 503 citations). These applications extend to NF-κB inhibition in cancer and inflammatory diseases (Park and Hong, 2016, 606 citations), supporting drug targeting in rheumatoid arthritis.
Reading Guide
Where to Start
"Thalidomide is an inhibitor of angiogenesis" by D’Amato et al. (1994) is the starting point for beginners, as its 2455 citations and clear demonstration of angiogenesis inhibition in a rabbit cornea assay provide foundational evidence of natural compounds' anti-tumor potential without requiring advanced molecular knowledge.
Key Papers Explained
D’Amato et al. (1994) in "Thalidomide is an inhibitor of angiogenesis" establishes angiogenesis inhibition, which Mitsiades et al. (2002) in "Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications" builds upon by showing direct apoptosis induction in myeloma. Liu et al. (2015) in "Treatment of Obesity with Celastrol" shifts to Celastrol's metabolic applications, while Yang et al. (2006) in "Celastrol, a Triterpene Extracted from the Chinese “Thunder of God Vine,” Is a Potent Proteasome Inhibitor and Suppresses Human Prostate Cancer Growth in Nude Mice" connects it to cancer via proteasome targeting. Titov et al. (2011) in "XPB, a subunit of TFIIH, is a target of the natural product triptolide" and Park and Hong (2016) in "Roles of NF-κB in Cancer and Inflammatory Diseases and Their Therapeutic Approaches" link Triptolide and NF-κB mechanisms, forming a progression from vascular to transcriptional and inflammatory targets.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current frontiers emphasize mechanistic refinement of Celastrol and Triptolide for pathway-specific therapies, as in Yang et al. (2006) proteasome inhibition and Titov et al. (2011) XPB targeting, with NF-κB approaches from Park and Hong (2016). No recent preprints or news indicate focus remains on preclinical validation and clinical translation of high-citation mechanisms like those in Liu et al. (2015) for obesity.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Thalidomide is an inhibitor of angiogenesis. | 1994 | Proceedings of the Nat... | 2.5K | ✓ |
| 2 | Treatment of Obesity with Celastrol | 2015 | Cell | 701 | ✓ |
| 3 | BCL-2 family isoforms in apoptosis and cancer | 2019 | Cell Death and Disease | 688 | ✓ |
| 4 | Apoptotic signaling induced by immunomodulatory thalidomide an... | 2002 | Blood | 666 | ✓ |
| 5 | Molecular Understanding and Modern Application of Traditional ... | 2007 | Cell | 642 | ✓ |
| 6 | Roles of NF-κB in Cancer and Inflammatory Diseases and Their T... | 2016 | Cells | 606 | ✓ |
| 7 | Inhibiting eukaryotic transcription. Which compound to choose?... | 2011 | Transcription | 584 | ✓ |
| 8 | Natural product and natural product derived drugs in clinical ... | 2014 | Natural Product Reports | 578 | ✕ |
| 9 | Celastrol, a Triterpene Extracted from the Chinese “Thunder of... | 2006 | Cancer Research | 576 | ✕ |
| 10 | XPB, a subunit of TFIIH, is a target of the natural product tr... | 2011 | Nature Chemical Biology | 503 | ✓ |
Frequently Asked Questions
What is Celastrol's mechanism in cancer treatment?
Celastrol, extracted from the Chinese Thunder God Vine, acts as a potent proteasome inhibitor that suppresses human prostate cancer growth in nude mice. Yang et al. (2006) in "Celastrol, a Triterpene Extracted from the Chinese “Thunder of God Vine,” Is a Potent Proteasome Inhibitor and Suppresses Human Prostate Cancer Growth in Nude Mice" demonstrated this effect through in vitro and in vivo studies. The compound's activity supports its potential in traditional medicine-based anticancer strategies.
How does Triptolide function in disease treatment?
Triptolide targets XPB, a subunit of TFIIH, inhibiting eukaryotic transcription. Titov et al. (2011) in "XPB, a subunit of TFIIH, is a target of the natural product triptolide" identified this mechanism using natural product screening. This action positions Triptolide for applications in conditions involving dysregulated transcription.
What role does Thalidomide play in natural compound research?
Thalidomide inhibits angiogenesis induced by basic fibroblast growth factor in rabbit cornea micropocket assays. D’Amato et al. (1994) in "Thalidomide is an inhibitor of angiogenesis" showed its oral administration blocks vessel growth. Its analogs also induce apoptosis in human multiple myeloma cells, per Mitsiades et al. (2002).
How do natural compounds target NF-κB in diseases?
NF-κB activation contributes to cancer and inflammatory diseases, and natural compounds inhibit this pathway. Park and Hong (2016) in "Roles of NF-κB in Cancer and Inflammatory Diseases and Their Therapeutic Approaches" outline therapeutic strategies targeting NF-κB. Compounds like Celastrol and Triptolide exemplify such inhibition in preclinical models.
What are applications of natural compounds in clinical settings?
Natural product-derived drugs include 100 compounds and 33 Antibody Drug Conjugates in clinical trials or registration by end of 2013. Butler et al. (2014) in "Natural product and natural product derived drugs in clinical trials" reviewed these, including launches since 2008. This supports ongoing translation from traditional medicines to modern therapies.
What is the current state of natural compounds research?
The field includes 12,337 works on compounds like Celastrol and Triptolide for inflammatory disorders, cancer, and rheumatoid arthritis. Key mechanisms involve NF-κB inhibition, apoptosis induction, and proteasome targeting. High-citation papers from 1994 to 2019 establish foundational evidence without recent preprints noted.
Open Research Questions
- ? How can Celastrol's proteasome inhibition be optimized to minimize toxicity in human cancer trials?
- ? What structural modifications of Triptolide enhance its specificity for XPB while reducing off-target transcription effects?
- ? Which NF-κB inhibitory pathways from Thunder God Vine compounds best translate to rheumatoid arthritis treatments?
- ? How do BCL-2 family interactions with natural apoptosis inducers like Thalidomide analogs improve multiple myeloma outcomes?
- ? What combinations of natural products with modern drugs maximize anti-angiogenic effects in solid tumors?
Recent Trends
The field maintains 12,337 works with no specified 5-year growth rate, anchored by papers from 1994 (D’Amato et al., 2455 citations) to 2019 (Warren et al., 688 citations).
High-impact studies like Liu et al. (2015, 701 citations) on Celastrol for obesity and Yang et al. (2006, 576 citations) on prostate cancer persist without new preprints or news in the last 12 months.
Research Natural Compounds in Disease Treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Natural Compounds in Disease Treatment with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers